Avandia's Black Box: FDA's Office of New Drugs Wins

The decision by FDA to add another "black box" warning to GalxoSmithKline's diabetes drug shows where the drug safety group stands on the agency's totem pole.

By Ramsey Baghdadi

The Food & Drug Administration settled a very public internal disagreement by adding another "black box" warning to GlaxoSmithKline’s diabetes...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet